Drug Profile
Research programme: checkpoint kinase 1 inhibitors - Vernalis
Latest Information Update: 28 Jul 2022
Price :
$50
*
At a glance
- Originator Vernalis
- Class Antineoplastics; Small molecules
- Mechanism of Action Checkpoint kinase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jul 2022 No recent reports of development identified for preclinical development in Cancer in United Kingdom (IV)
- 15 Jul 2020 Preclinical development is ongoing in United Kingdom (IV) (Vernalis pipeline, July 2020)
- 10 Oct 2018 Vernalis has been acquired by Ligand Pharmaceuticals